Hurvitz: CDK4/6 Inhibitors With Endocrine Therapy Is the “Gold Standard” in the First Line for HR+, HER2-Negative Advanced Breast Cancer

Sara A. Hurvitz, MD, of UCLA Health spoke with The American Journal of Managed Care® (AJMC®) about advanced hormone receptor–positive (HR+), HER2-negative breast cancer and the emergence of CDK4/6 inhibitors with endocrine therapy as the “gold standard” for first-line treatment.